Current status of newer carbapenems

Current Medicinal Chemistry

Volumn 16, Issue 5, 2009, Pages 564-575

  Bassetti, Matteo ^a   Nicolini, Laura ^a   Esposito, Silvano ^b   Righi, Elda ^a   Viscoli, Claudio ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Biapenem; Carbapenems; Doripenem; Ertapenem; Imipenem; Meropenem; Panipenem; Tebipenem pivoxil

Indexed keywords

BIAPENEM; CEFEPIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; PANIPENEM PLUS BETAMIPRON; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; TEBIPENEM PIVOXIL; TOMOPENEM; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL PNEUMONIA; BACTEROIDES FRAGILIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CREATININE CLEARANCE; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENTEROBACTERIACEAE; EOSINOPHILIA; ERYTHEMA; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; GRAM NEGATIVE INFECTION; GYNECOLOGIC INFECTION; HALF LIFE TIME; HOSPITAL INFECTION; HUMAN; INFECTION; INTRAUTERINE INFECTION; LOWER RESPIRATORY TRACT INFECTION; LUNG INFECTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PELVIC INFLAMMATORY DISEASE; PERITONITIS; PHLEBITIS; PLASMA HALF LIFE; PLASMA PROTEIN BINDING; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SKIN INFECTION; SOMNOLENCE; STREPTOCOCCUS PNEUMONIAE; SURGICAL INFECTION; THROMBOPHLEBITIS; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; WOUND INFECTION;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CARBAPENEMS; DRUG RESISTANCE, MICROBIAL;

EID: 63149127459     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787458498     Document Type: Review

References (152)

1. Turner, P.J. Meropenem activity against European isolates: Report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn. Microbiol. Infect. Dis., 2008, 60, 185-92.
2. Zhanel, G.G.; Wiebe, R.; Dilay, L.; Thomson, K.; Rubinstein, E.; Hoban, D.J.; Noreddin, A.M. Comparative review of the carbapenems. Drugs, 2007, 67, 1027-52.
3. Maveyraud, L.; Mourey, L.; Kotra, LP.; Pedelacq, J.D.; Guillet, V.; Mobashery, S.; Samama, J.P. Structural Basis for Clinical Longevity of Carbapenem Antibiotics in the Face of Challenge by the Common Class A β-Lactamases from the Antibiotic-Resistant Bacteria. J. Am. Chem. Soc., 1998, 120, 9748-52.
4. Livermore, D.M.; Neil, W. Carbapenemases: A problem in waiting? Curr. Opin. Microbiol., 2000, 3, 489-95.
5. Mody R.M.; Erwin, D.P.; Summers, A.M.; Carrero, H.A.; Selby, E.B.; Ewell, A.J.; Moran, K.A. Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms. Ann. Clin. Microbiol. Antimicrob., 2007, 6, 6.
6. Rasmussen, B.A.; Bush, K. Carbapenem-hydrolyzing blactamases. Antimicrob. Agents Chemother., 1997, 41, 223-32.
7. Cai, J.C.; Zhou, H.W.; Chen, G.X.; Zhang, R. Detection of plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in a strain of carbapenem-resistant Enterobacter cloacae. Zhonghua Yi Xue Za Zhi, 2008, 88, 135-8.
8. Cuzon,G.; Naas, T.; Demachy, M.C.; Nordmann, P. Plasmid-Mediated Carbapenem-Hydrolyzing {beta}-Lactamase KPC-2 in Klebsiella pneumoniae from Greece. Antimicrob. Agents Chemother., 2008, 52, 796-7.
9. Gülmez, D.; Woodford, N.; Palepou, M.F.; Mushtaq, S.; Metan, G.; Yakupogullari, Y.; Kocagoz, S.; Uzun, O.; Hascelik, G.; Livermore, D.M. Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss. Int. J. Antimicrob. Agents, 2008, 31, 523-6.
10. Sanschagrin, F.; Couture, F.; Levesque, R.C. Primary structure of OXA-3 and phylogeny of oxacillin-hydrolyzing class D beta-lactamases. Antimicrob. Agents Chemother., 1995, 39, 887-93.
11. Hornstein, M.; Sautjeau-Rostoker, C.; Péduzzi, J.; Vessières, A.; Hong, L.T.; Barthélémy, M.; Scavizzi, M.; Labia, R. Oxacillin-hydrolyzing beta-lactamase involved in resistance to imipenem in Acinetobacter baumannii. FEMS Microbiol. Lett., 1997, 153, 333-9.
12. Jacoby, G.A.; Munoz-Price, L.S. The new beta-lactamases. N. Engl. J. Med., 2005, 352, 380-91.
13. Lu, P.L.; Huang, L.Y.; Lian, S.T.; Chang, K.; Lin, C.L.; Hwang, I.J.; Chiang, W.G.; Chen, Y.H.; Lin, S.F.; Siu, L.K. How carbapenem-resistant Acinetobacter spp. established in a newly constructed hospital. Int. J. Antimicrob. Agents., 2008, 31, 463-6.
14. Queenan, A.M.; Bush, K. Carbapenemases: The versatile beta-lactamases. Clin. Microbiol. Rev., 2007, 20, 440-58.
15. Fish, D.N. Meropenem in the treatment of complicated skin and soft tissue infections. Ther. Clin. Risk Manag., 2006, 2, 401-15.
16. Doménech-Sánchez, A.; Martínez-Martínez, L.; Hernández-Allés, S.; del Carmen Conejo, M.; Pascual, A.; Tomás, J.M.; Albertí, S.; Benedí, V.J. Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob. Agents Chemother., 2003, 47, 3332-5.
17. Rice, L.B.; Bonomo, R.A. Beta-lactamases: Which ones are clinically important? Drug Resist. Updates, 2000, 3, 178-89
18. Bassetti, M.; Righi, E.; Viscoli, C. Novel beta-lactam antibiotics and inhibitor combinations. Expert Opin. Investig. Drugs, 2008, 17, 285-96.
19. Balfour, J.A.; Bryson, H.M.; Brogden, R.N. Imipenem/cilastatin: An update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs, 1996, 51, 99-136.
20. Joseph, J.; Rodvold, K.A. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opin. Pharmacother., 2008, 9, 561-75.
21. Vergidis, P.I.; Falagas, M.E. Multidrug-resistant Gram-negative bacterial infections: The emerging threat and potential novel treatment options. Curr. Opin. Investig. Drugs, 2008, 9, 176-83.
22. Mouton, J.; Touw, D.; Horrevorts, A.; Vinks, A. Comparative Pharmacokinetics of the Carbapenems: Clinical Implications. Clin. Pharmacokinetics, 2000, 39, 185-201.
23. Moczygemba, L.R. Frei, C.R.; Burgess, D.S. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended- spectrum beta-lactamases. Clin. Ther., 2004, 26, 1800-7.
24. Matsumoto, T.; Muratani, T. Newer carbapenems for urinary tract infections. Int. J. Antimicrob. Agents, 2004, 24, S35-8.
25. Perry, C.M.; Ibbotson, T. Biapenem. Drugs, 2002, 62, 2221-34.
26. Kobayashi, R.; Konomi, M.; Hasegawa, K.; Morozumi, M.; Sunakawa, K.; Ubukata, K. In vitro activity of tebipenem, a new oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae. Antimicrob. Agents Chemother., 2005, 49, 889-94.
27. Ohtake, N.; Imamura, H.; Jona, H.; Kiyonaga, H.; Shimizu, A.; Moriya, M.; Sato, H.; Nakano, M.; Ushijima, R.; Nakagawa, S. Novel dithiocarbamate carbapenems with anti-MRSA activity. Bioorg. Med. Chem., 1998, 6, 1089-101.
28. Guignard, B.; Entenza, J.M.; Moreillon, P. Beta-lactams against methicillin-resistant Staphylococcus aureus. Curr. Opin. Pharmacol., 2005, 5, 479-89.
29. Sumita, Y.; Nouda, H.; Kanazawa, K.; Fukasawa, M. Antimicrobial activity of SM-17466, a novel carbapenem antibiotic with potent activity against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother., 1995, 39, 910-6.
30. Ueda, Y.; Sunagawa, M. In vitro and in vivo activities of novel 2- (thiazol-2-ylthio)-1beta-methylcarbapenems with potent activities against multiresistant gram-positive bacteria. Antimicrob. Agents Chemother., 2003, 47, 2471-80.
31. Fukuoka, T.; Koga, T.; Ishii, C.; Kitayama, A.; Namba, E.; Abe, T.; Nakagawa, M.; Matsushita, Y.; Shibayama, T.; Hirota, T. CS-023 (R-115685), a novel parenteral carbapenem: II. In vitro and in vivo activities against methicillin-resistant Staphylococcus aureus. 41st Intersci. Conf. Antimicrob. Agents Chemother., 2001, F-366.
32. Nagano, R.; Shibata, K.; Naito, T.; Fuse, A.; Asano, K.; Hashizume, T.; Nakagawa, S. Therapeutic efficacy of BO-3482, a novel dithiocarbamate carbapenem, in mice infected with methicillin-resistant Staphylococcus aureus: Antimicrob. Agents Chemother., 1997, 41, 2278-81.
33. Koga, T.; Masuda, N.; Kakuta, M.; Namba, E.; Sugihara, C.; Fukuoka, T. Potent in vitro Activity of Tomopenem (CS-023) against Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 2008, 52, 2849-54.
34. MacGowan, A.P.; Bowker, K.E.; Noel, A.R. Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection. Antimicrob. Agents Chemother., 2008, 52, 1401-6.
35. Mallalieu, N.L.; Lennon, S.; Liu, M.; Kirkpatrick, C.; Robson, R.; Luedin, E.; Davies, B.E. Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem. Antimicrob. Agents Chemother., 2008, 52, 2360-6.
36. Macgowan, A.P.; Bowker, K.E.; Noel, A.R. Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection. Antimicrob. Agents Chemother., 2008, 52, 1401-6.
37. Solomkin, J.S.; Reinhart, H.H.; Dellinger, E.P.; Solomkin, J.S.; Reinhart, H.H.; Dellinger, E.P.; Bohnen, J.M.; Rotstein, O.D.; Vogel, S.B.; Simms, H.H.; Hill, C.S.; Bjornson, H.S.; Haverstock, D.C.; Coulter, H.O.; Echols, R.M. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann. Surg., 1996, 223, 303-15.
38. Yellin, A.E.; Hassett, J.M.; Fernandez, A.; Geib, J.; Adeyi, B.; Woods, G.L.; Teppler, H. Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. Int. J. Antimicrob. Agents, 2002, 20, 165-73.
39. Roy, S.; Higareda, I.; Angel-Muller, E.; Ismail, M.; Hague, C.; Adeyi, B.; Woods, G.L.; Teppler, H. Protocol 023 Study Group. Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: A prospective, multicenter randomized, double-blind study. Infect. Dis. Obstet. Gynecol., 2003, 11, 27-37.
40. Jimenez-Cruz, F.; Jasovich, A.; Cajigas, J.; Jiang, Q.; Imbeault, D.; Woods, G.L.; Gesser, R.M. Protocol 021 Study GroupA prospective, multicenter, randomized, doble-blind study comparing ertapenem and ceftriaxone followed by appropriated oral therapy for complicated urinary tract infections in adults. Urology, 2002, 60, 16-22.
41. Graham, D.R.; Lucasti, C.; Malafaia, O.; Nichols, R.L.; Holtom, P.; Perez, N.Q.; McAdams, A.; Woods, G.L.; Ceesay, T.P.; Gesser, R. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin. Infect. Dis., 2002, 34, 1460-8.
42. Tomera, K.M.; Burdmann, E.A.; Reyna, O.G.; Jiang, Q.; Wimmer, W.M.; Woods, G.L.; Gesser, R.M. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: Results of a prospective, randomized, double-blind multicenter study. Antimicrob. Agents Chemother., 2002, 46, 2895-900.
43. Lipsky, B.A.; Armstrong, D.G.; Citron, D.M.; Tice, A.D.; Morgenstern, D.E.; Abramson, M.A. Ertapenem versus piperacillintazobactam for diabetic foot infections (SIDE-STEP); prospective, randomised, controlled, double-blind, multicenter trial. Lancet, 2005, 366, 1695-703.
44. Ortiz-Ruiz, G.; Caballero-Lopez, J.; Friedland, I.R.; Woods, G.L.; Carides, A. Protocol 018 Ertapenem Community-Acquired Pneumonia Study Group. A study evaluating the efficacy, safety and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin. Infect. Dis., 2002, 34, 1076-83.
45. Vetter, N.; Cambronero-Hernandez, E.; Rohlf, J.; Simon, S.; Carides, A.; Oliveria, T.; Isaacs, R. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community- acquired pneumonia. Clin. Ther., 2002, 24, 1770-85.
46. Jones, R.N.; Sader, H.S.; Fritsche, T.R. Comparative activity of doripenem and three other carbapenems tested against Gramnegative bacilli with various beta-lactamase resistance mechanisms. Diagn. Microbiol. Infect. Dis., 2005, 52, 71-4.
47. Fritsche, T.R.; Stillwell, M.G.; Jones, R.N. Antimicrobial activity of doripenem (S-4661): A global surveillance report (2003). Clin. Microbiol. Infect., 2005, 11, 974-84.
48. Performance standards for antimicrobial susceptibility testing: fifteenth informational supplement. Clin. Lab. Standards Inst., 2005, 25, M100-S15.
49. Ge, Y.; Wikler, M.A.; Sahm, D.F.; Blosser-Middleton, R.S.; Karlowsky, J.A. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob. Agents Chemother., 2004, 48, 1384-96.
50. Jacoby, G.A.; Mills, D.M.; Chow, N. Role of β-lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae Antimicrob. Agents Chemother., 2004, 48, 3203-6.
51. Paterson, D.L.; Rossi, F.; Baquero, F.; Hsueh, P.R.; Woods, G.L.; Satishchandran, V.; Snyder, T.A.; Harvey, C.M.; Teppler, H.; Dinubile, M.J.; Chow, J.W. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intraabdominal infections worldwide: The 2003 Study for Monitoring Antimicrobial Resistance trends (SMART). J. Antimicrob. Chemother., 2005, 55, 965-73.
52. Burkhardt, O.; Kumar, V.; Katterwe, D.; Majcher-Peszynska, J.; Drewelow, B.; Derendorf, H.; Welte, T. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: Pharmacokinetics with special consideration of free-drug concentration. J. Antimicrob. Chemother., 2007, 59, 277-84.
53. Pletz, M.W.; Rau, M.; Bulitta, J.; De Roux, A.; Burkhardt, O.; Kruse, G.; Kurowski, M.; Nord, C.E.; Lode, H. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob. Agents Chemother., 2004, 48, 3765-72.
54. Bassetti, M.; Righi, E.; Fasce, R.; Molinari, M.P.; Rosso, R.; Di Biagio, A.; Mussap, M.; Pallavicini, F.B.; Viscoli, C. Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit. J. Antimicrob. Chemother., 2007, 60, 433-5.
55. Hikida, M.; Kawashima, K.; Yoshida, M. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex. J. Antimicrob. Chemother, 1992, 30, 129-34.
56. Meiji. Omegacin® (biapenem) prescribing information. Kanagawa, Japan: Meiji, 2002.
57. Nakashima, M.; Uematsu, T.; Ueno, K. Phase 1 study of L-627, biapenem, a new parenteral carbapenem antibiotic. Int. J. Clin. Pharmacol. Ther. Toxicol., 1993, 31, 70-6.
58. Koeppe, P.; Hoffler, D.; Fitzen, B. Biapenem pharmacokinetics in healthy volunteers and in patients with impaired renal function. Arzneimittelforschung, 1997, 47, 1250-6.
59. Hoban, D.J.; Jones, R.N.; Yamane, N.; Frei, R.; Trilla, A.; Pignatari, A.C. In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide Diagn. Microbiol. Infect. Dis., 1993, 17, 299-305.
60. Watanabe, A.; Kikuchi, H.; Kikuchi, T.; Lutfor, A.B.; Tokue, Y.; Takahashi, H.; Fujimura, S.; Shoji, S.; Honda, Y.; Nakai, Y.; Nukiwa, T. Comparative in vitro activity of carbapenem antibiotics against respiratory pathogens isolated in recent years. J. Infect. Chemother., 1999, 5, 171-5.
61. Igari, J.; Watanabe, N.; Uehara, N.; Inoue, M.; Yoshida, H.; Imafuku, Y.; Nishino, T.; Shibano, T.; Satou, S.; Kobayashi, I.; Takahashi, A.; Yomoda, S.; Matsuoka, K.; Oguri, T.; Ohba, Y.; Kumasaka, K.; Tokuda, K.; Kobayashi, Y.; Hongo, T.; Okada, J.; Sasaki, T.; Matsumoto, N.; Hirata, Y.; Nakasaki, N.; Ono, J.; Takata, T.; Kawaguchi, R.; Ohtaki, Y.; Kajimura, K.; Ishigo, S.; Hashimoto, T.; Aoki, N.; Okamoto, E.; Murakami, E.; Saeki, H. Changes in the antibacterial activity of chemotherapeutic agents (especially carbapenems) for 10 species of clinical isolates between 1994 and 1996. Surveillance group of the sensitivities of clinical isolates to antibacterial agents. Jpn. J. Antibiot., 2000, 53, 157-70.
62. Raymond, N.J.; Bremner, D.A. The in-vitro activity of biapanem against 964 clinical isolates of aerobic bacteria. J. Antimicrob. Chemother., 1995, 35, 681-6.
63. Murase, M. In vitro antibacterial activities of carbapenems against clinical isolates. Jpn. J. Antibiot., 1999, 52, 667-79.
64. Spangler, S.K.; Jacobs, M.R.; Appelbaum, P.C. Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob. Agents Chemother., 1994, 38, 898-900.
65. Suzuki, Y.; Nishinari, C.; Endo, H.; Tamura, C.; Jinbo, K. Antimicrobial activities of carbapenems and forth generation cephems against clinically isolated strains Jpn. J. Antibiot. 2001, 54, 473-90.
66. Alonso, R.; Fernández-Aranguiz, A.; Colom, K.; Morla, A.; Suinaga, E.; Umaran, A.; Cisterna, R. In vitro activity of biapenem against beta-lactamase producing Enterobacteriaceae. Eur. J. Clin. Microbiol. Infect. Dis., 1994, 13, 820-2.
67. Chen, H.Y.; Livermore, D.M. Comparative in-vitro activity of biapenem against enterobacteria with beta-lactamase-mediated antibiotic resistance. J. Antimicrob. Chemother., 1994, 33, 453-64.
68. Hirakata, Y.; Matsuda, J.; Mochida, C. Annual changes is susceptibility of clinical isolates to biapenem. Jpn. J. Chemother., 2002, 50, 329-51.
69. Ubukata, K.; Chiba, N.; Kobayashi, R. Comparison of in vitro activity of biapenem with other antimicrobial agents against clinical isolates of Pseudomonas aeruginosa. Chemother. Jpn., 2002, 50, 1-10.
70. Miyake, Y.; Fujiwara, S.; Usui, T. In vitro antibacterial activity of biapenem against adherent bacteria. Chemother., 1994, 42, 82-90.
71. Aldridge, K.E.; Morice, N.; Schiro, D.D. In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes. Antimicrob. Agents Chemother., 1994, 38, 889-93.
72. Wexler, H.M.; Molitoris, E.; Finegold, S.M. The in-vitro activity of L-627 against anaerobic bacteria. J. Antimicrob. Chemother., 1994, 33, 629-34.
73. Appelbaum, P.C.; Spangler, S.K.; Jacobs, M.R. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam. J. Antimicrob. Chemother., 1993, 32, 223-31.
74. Brismar, B.; Akerlund, J.E.; Sjöstedt, S.; Johansson, C.; Törnqvist, A.; Bäckstrand, B.; Bång, H., Andåker, L.; Gustafsson, P.O.; Darle, N.; Angerås, M.; Falk, A.; Tunevall, G.; Kasholm-Tengve, B.; Skau, T.; Nyström, P.O.; Gasslander, T.; Hagelbäck, A.; Olsson-Liljequist, B.; Eklund, A.E.; Nord, C.E. Biapenem versus imipenem/cilastatin in the treatment of complicated intraabdominal infections: Report from a Swedish Study. Scand. J. Infect. Dis., 1996, 28, 507-12.
75. Matsumoto, F.; Imai, T.; Sakurai, I. A comparative study of biapenem and imipenem/cilastatin for chronic respiratory tract infections Jpn. J. Chemother., 1995, 43, 63-84.
76. Matsumoto, F.; Inoue, M.; Sakurai, I. A comparative study of biapenem and imipemem/cilastatin in lower respiratory infections. Jpn. J. Chemother., 2000, 48, 45-67.
77. Panipenem/betamipron (Carbenin) prescribing information. Sankyo Co., Ltd. 2001.
78. Hirouchi, Y.; Naganuma, H.; Kawahara, Y.; Okada, R.; Kamiya, A.; Inui, K.; Hori, R. Preventive effect of betamipron on nephrotoxicity and uptake of carbapenems in rabbit renal cortex. Jpn. J. Pharmacol., 1994, 66, 1-6.
79. Hikida, M.; Kawashima, K.; Yoshida, M.; Mitsuhashi, S. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex.. J. Antimicrob. Chemother., 1992, 30, 129-34.
80. Inoue, K.; Hamana, Y.; Mitsuhashi, S. Antibacterial activity of panipenem, a new carbapenem antibiotic. Chemotherapy, 1991, 39, 1-13.
81. Nomura, S.; Nagayama, A. In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections. J. Chemother., 2002, 14, 155-60.
82. Watanabe, A.; Tokue, Y.; Takahashi, H.; Kikuchi, T.; Kobayashi, T.; Gomi, K.; Fujimura, S.; Yasui, S.; Murayama, Y.; Nukiwa, T. Comparative in-vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000. J. Infect. Chemother., 2001, 7, 267-71.
83. Fukuoka, T.; Inoue, H.; Abe, T.; Ohya, S. In vitro and in vivo activities clinical evaluation of panipenem/betamipron, a new carbapenem antibiotic. Chemotherapy, 1991, 39, 365-71.
84. Higa, F.; Irabu, Y.; Fukuhara, H. Laboratory and clinical studies on panipenem/betamipron. Chemotherapy, 1991, 39, 449-54.
85. Goto, Y.; Ichimiya, T.; Ikuta, M. In vitro antibacterial activity of panipenem/betamipron, a carbapenem antibiotic. Chemotherapy, 1991, 39, 441-8.
86. Goto, T.; Makinose, S.; Kawahara, M. Antimicrobial activity and clinical evaluation of panipenem/betamipron in urinary tract infections. Chemotherapy, 1991, 39, 512-20.
87. Nomura, S.; Nagayama, A. In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections. J. Chemother., 2002, 14, 155-60.
88. Totsuka, K.; Kikuchi, K.; Shibata, Y. Study on postantibiotic effect (PAE) of panipenem/betamipron, a carbapenem antibiotic. Chemotherapy, 1991, 39, 78-82.
89. Kurata, K. Investigation of panipenem/betamipron levels in sera and various tissues in patients of orthopedic surgery. Jpn. J. Antibiot., 1992, 45, 155-9.
90. Suzuki, K.; Horiba, M.; Naide, Y. Clinical study on panipenem/betamipron in bacterial prostatitis. Chemotherapy, 1991, 39, 773-7.
91. Yamamoto, T.; Yasuda, J.; Iwasaku, K. Basic and clinical studies on panipenem/betamipron in obstetrics and gynecology. Chemotherapy, 1991, 39, 636-46.
92. Hara, K.; Hiraga, Y.; Omichi, M. A comparative study of panipenem/ betamipron and imipenem/cilastatin in bacterial pneumonia. Chemotherapy, 1992, 40, 509-31.
93. Hara, K.; Kouno, S.K.H., Takebe, K. A comparative study of panipenem/ betamipron and imipenem/cilastatin in respiratory tract infections. Chemotherapy, 1992, 40, 613-37.
94. Kumazawa, J.; Matsumoto, T.; Kumamoto, Y. Phase III comparative clinical trial of panipenem/betamipron (PAPM/BP) with imipenem/cilastatin sodium (IPM/CS) in complicaed urinary tract infections. Nishinihon J. Urol., 1992, 54, 254-71.
95. Chimura, T.; Oda, T.; Saito, N.; Morisaki, N.; Numasaki, M. Change of cytokines and clinical efficacy of panipenem/betamipron in obstetric and gynecological infections. Yamagata Study Group of Panipenem/Betamipron in Obstetric and Gynecological Infections. Jpn. J. Antibiot., 1998, 51, 37-45.
96. Yura, J.; Shinagawa, N.; Ishikawa, S. Fundamental and clinical studies of panipenem/betamipron in surgery. Chemotherapy, 1991, 39, 557-71.
97. Tsuyuki, K.; Arisawa, Y.; Yokoyama, I. Studies on the efficacy and safety of panipenem/betamipron in infections in surgical domain and the safety when mixed with lactate containing infusion. Jpn. J. Antibiot., 1992, 45, 188-96.
98. Nakayama, I.; Yamaji, E.; Kawamura, H. Study on surgical infections, especially intra-abdominal infections, postoperative infections, and skin and soft tissue infections:cLinical application of panipenem/ betamipron, a new carbapenem antibiotic for injection. Chemotherapy, 1991, 39, 534-51.
99. Kwon, K.; Cheong, H.S.; Rhee, J. Panipenem Versus Cefepime as Empirical Monotherapy in Adult Cancer Patients with Febrile Neutropenia: A Prospective Randomized Trial. Jap. J. Clin. Oncol., 2008, 38, 49-55.
100. Kato, T.; Goshima, T.; Akita, H. Clinical and bacteriological studies on panipenem/betamipron in pediatrics. Kanagawa Research Group for Infectious Diseases of Children. Jpn. J. Antibiot., 1998, 51, 286-97.
101. Anonymous. Discussion on the safety of panipenem/betamipron according to postmarketing surveillance. Jpn. J. Chemother., 1999, 47, 396-410.
102. Hara, K.; Hiraga, Y.; Omichi, M. A comparative study of panipenem/ betamipron and imipenem/cilastatin in bacterial pneumonia. Chemotherapy, 1992, 40, 509-31.
103. Sunagawa, M.; Matsumura, H.; Sumita, Y.; Nouda, H. Structural features resulting in convulsive activity of carbapenem compounds: Effect of C-2 side chain. J. Antibiot. (Tokyo), 1995, 48, 408-16.
104. Kurihara, A.; Hisaoka, M.; Mikuni, N.; Kamoshida, K. Neurotoxicity of panipenem/betamipron, a new carbapenem, in rabbits: Correlation to concentration in central nervous system. J. Pharmacobiodyn., 1992, 15, 325-32.
105. Ge, Y.; Wikler, M.A.; Sahm, D.F.; Blosser-Middleton, R.S.; Karlowsky, J.A. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob. Agents Chemother., 2004, 48, 1384-96.
106. Anderson, D.L. Doripenem. Drugs Today (Barc.), 2006, 42, 399-404.
107. Peninsula Pharmaceuticals Inc. Peninsula Pharmaceuticals, Inc. announces results of preclinical study comparing nebulized doripenem vs tobramycin in a murine model of acute, severe Pseudomonas aeruginosa pneumonia. Available at: www.peninsulapharm.com. Accessed April 7, 2004.
108. Floren, L.; Wikler, M.; Kilfoil, T. A phase 1, double-blind, placebo-controlled study to determine the safety, tolerability, and pharmacokinetics of prolonged-infusion regimens of doripenem in healthy subjects. 44th Intersci. Conf. Antimicrob. Agents Chemother., 2004, PA-16.
109. Jones, R.N.; Huynh, H.K.; Biedenbach, D.J.; Fritsche, T.R.; Sader, H.S. Doripenem (S-4661), a novel carbapenem: Comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J. Antimicrob. Chemother., 2004, 54, 144-54.
110. Ikawa, K.; Morikawa, N.; Urakawa, N.; Ikeda, K.; Ohge, H.; Sueda, T. Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients. J. Antimicrob. Chemother., 2007, 60, 1395-7.
111. Watanabe, A.; Takahashi, H.; Kikuchi, T.; Kobayashi, T.; Gomi, K.; Fujimura, S.; Tokue, Y.; Nukiwa, T. Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens. Chemotherapy, 2000, 46, 184-87.
112. Bhavnani, S.M.; Hammel, J.P.; Cirincione, B.B.; Wikler, M.A.; Ambrose, P.G. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob. Agents Chemother., 2005, 49, 3944-7.
113. Mushtaq, S.; Ge, Y.; Livermore, D.M. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized blactamases. Antimicrob. Agents Chemother., 2004, 48, 1313-19.
114. Wiseman, L.R.; Wagstaff, A.J.; Brogden, R.N.; Bryson, H.M.. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs, 1995, 50, 73-101.
115. Jones, R.N.; Huynh, H.K.; Biedenbach, D.J. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob. Agents Chemother., 2004, 48, 3136-40.
116. Solomkin, J.; Umeh, O.; Jiang, J.; Kaniga, K.; Friedland, I. Doripenem vs meropenem with an option for oral step-down therapy in the treatment of complicated intra-abdominal infections. 47th Intersci. Conf. Antimicrob. Agents Chemother., 2007, L-487.
117. Rea-Neto, A.; Niederman, M.; Prokicimer, P.; Lee, M.; Kaniga, K.; Friedland, I. Efficacy and safety of intravenous doripenem vs piperacillin/tazobactam in nosocomial pneumonia. 4th Intersci. Conf. Antimicrob. Agents Chemother., 2007, L-731.
118. Chastre, J.; Wunderink, R.; Prokocimer, P.; Lee, M.; Kaniga, K.; Friedland, I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study. Crit. Care Med., 2008, 36, 1089-96.
119. Goldstein, E.J.; Citron, D.M.; Merriam, C.V.; Warren, Y.A.; Tyrrell, K.L.; Fernandez, H.T. In vitro Activity of Doripenem and Six Comparator Drugs Against 423 Aerobic and Anaerobic Bacteria Isolated from Infected Diabetic Foot Wounds. Antimicrob. Agents Chemother., 2008, 52, 761-6.
120. Maruyama, T.; Yamamoto, Y.; Kano, Y.; Kurazono, M.; Matsuhisa, E.; Takata, H.; Takata, T.; Atsumi, K.; Iwamatsu, K.; Shitara E. CP5484, a novel quaternary carbapenem with potent anti-MRSA activity and reduced toxicity. Bioorg. Med. Chem., 2007, 15, 6379- 7.
121. Thye, D.A.; Kilfoilm, T.; Leighton, A. Doripenem: A phase 1 study to evaluate safety, tolerability and pharmacokinetics in a Western healthy volunteer population 43rd Intersci. Conf. Antimicrob. Agents Chemother., 2003, PA-21.
122. Miyazaki, S.; Hosoyama, T.; Furuya, N.; Ishii, Y.; Matsumoto, T.; Ohno, A.; Tateda, K.; and Yamaguchi, K. In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections. Antimicrob. Agents Chemother., 2001, 45, 203-7.
123. Hikida, M.; Itahashi, K.; Igarashi, A.; Shiba, T.; Kitamura, M. In vitro antibacterial activity of LJC 11,036, an active metabolite of L-Bassetti 084, a new oral carbapenem antibiotic with potent antipneumococcal activity. Antimicrob. Agents Chemother., 1999, 43, 2010-6.
124. Kobayashi, R.; Konomi, M.; Hasegawa, K.; Morozumi, M.; Sunakawa, K.; Ubukata, K. In vitro activity of tebipenem, a new oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae. Antimicrob. Agents Chemother., 2005, 49, 889-94
125. Yokokawa, M.; Yano, M.; Nakashima, M. 39th Intersci. Conf. Antimicrob. Agents Chemother., 1999, F388.
126. Jones, M.E.; Brown, N.P.; Dannemann, B.; Sahm, D. F. 46th Intersci. Conf. Antimicrob. Agents Chemother., 2006, E-0227.
127. Koga, T.; Masuda, N.; Kakuta, M.; Namba, E.; Sugihara, C.; Fukuoka, T. Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 2008, 52, 2849-54
128. Jones, M. E.; Brown, N. P.; Dannemann, B.; Sahm, D. F. 46th Intersci. Conf. Antimicrob. Agents Chemother., 2006, C1-0035.
129. Sugihara, K.; Matsushita, Y.; Yamamura, N.; Uemori, M.; Sugihara, C.; Tokumitsu, A.; Inoue, H.; Kakuta, M.; Namba, E.; Nasu, H.; Koga, T. 48th Intersci. Conf. Antimicrob. Agents Chemother., 2008, A-027.
130. Solomkin, J.; Teppler, H.; Graham, D.R.; Gesser, R.M.; Meibohm, A.R.; Roy, S.; Woods, G.L. Treatment of polymicrobial infections: Post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam. J. Antimicrob. Chemother., 2004, 53, 51-7.
131. Dela Pena, A.S.; Asperger, W.; Köckerling, F.; Raz, R.; Kafka, R.; Warren, B.; Shivaprakash, M.; Vrijens, F.; Giezek, H.; DiNubile, M.J.; Chan, C.Y. Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. J. Gastrointest. Surg., 2006, 10, 567-74.
132. Navarro, N.S. Jr; Campos, M.I.; Alvarado, R.; Quintero, N.; Branicki, F.J.; Wei, J.; Shivaprakash, M.; Vrijens, F.; Giezek, H.; Chan, C.Y.; Di Nubile, M.J. Ertapenem versus ceftriaxone and metronidazole as treatment for complicated intra-abdominal infections Int. J. Surg., 2005, 3, 25-34.
133. Laethem, T.; De Lepeleire, I.; McCrea J.; Zhang, J.; Majumdar, A.; Musson, D.; Rogers, D.; Li, S.; Guillaume, M.; Parneix-Spake A.; Deutsch, P. Penetration by Ertapenem, a Parenteral Carbapenem Administered Once Daily, in Suction-Induced Skin Blister Fluid in Healthy Young Volunteers. Antimicrob. Agents Chemother., 2003, 47, 1439-42.
134. Jones, R.N.; Huynh, H.K.; Biedenbach, D.J.; Fritsche, T.R.; Sader, H.S. Doripenem (S-4661), a novel carbapenem: Comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J. Antimicrob. Chemother., 2004, 54, 144-54.
135. Mushtaq, S.; Ge, Y.; Livermore, D.M. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized betalactamases. Antimicrob. Agents Chemother., 2004, 48, 1313-9.
136. Choi, S.H.; Park, S.J.; Jun, J.B.; Lee, S.R.; Jeon, M.H.; Kwon, H.H.; Kim, S.C.; Kim, M.N.; Jeong, J.Y.; Woo, J.H.; Kim, Y.S. Comparative in vitro activities of carbapenem antimicrobial agents against 264 penicillin-resistant Streptococcus pneumoniae isolates from Korea. Diagn. Microbiol. Infect. Dis., 2007, 58, 141-3.
137. Goldstein, E.J.; Citron, D.M.; Merriam, C.V.; Warren, Y.A.; Tyrrell, K.L.; Fernandez, H.T. In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. Antimicrob. Agents Chemother., 2008, 52, 761-6.
138. Traczewski, M.M.; Brown, S.D. In vitro Activity of Doripenem against Pseudomonas aeruginosa and Burkholderia cepacia Isolates from both Cystic Fibrosis and Non-Cystic Fibrosis Patients. Antimicrob. Agents Chemother., 2006, 50, 819-21.
139. Ambler, R.P.; Coulson A.F.W.; Frere J. M.; Ghuysen J. M.; Joris B.; Forsman, M.; Levesque, R.C.; Tiraby, G.; Waley, S.G. A standard numbering scheme for the class A β-lactamases. Biochem. J., 1991, 276, 269-70.
140. Yang, Y.; Wu, P.; Livermore, D.M. Biochemical characterization of a beta-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates. Antimicrob. Agents Chemother., 1990, 34, 755-58.
141. Woodford, N.; Tierno, P.M. Jr.; Young, K.; Tysall, L.; Palepou, M.F I.; Ward, E.; Painter, R.E.; Suber, D.F.; Shungu, D.; Silver, L.L.; Inglima, K.; Kornblum, J.; and Livermore, D.M. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York medical center. Antimicrob. Agents Chemother., 2004, 48, 4793-99.
142. Medeiros, A.A.; Hare, R.S. Beta-Lactamase-mediated resistance to penems and carbapenems amongst Enterobacteriaceae. 26th Intersci. Conf. Antimicrob. Agents Chemother., 1996, PA-116.
143. Miriagou, V.; Tzouvelekis, L.S.; Rossiter, S.; Tzelepi, E.; Angulo F. J.; Whichard J. M. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob. Agents Chemother., 2003, 47, 1297-300.
144. Poirel, L.; Le Thomas, I.; Naas, T.; Karim, A.; Nordmann, P. Biochemical sequence analyses of GES-1, a novel class A extended-spectrum beta-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae. Antimicrob. Agents Chemother., 2000, 44, 622-32.
145. Walsh, T.R. The emergence and implications of metallo-betalactamases in Gram-negative bacteria Clin. Microbiol. Infect., 2005, 11, 2-9.
146. Walsh, T.R.; Toleman, M.A.; Poirel, L.; Nordmann, P. Metallobeta-lactamases: The quiet before the storm? Clin. Microbiol. Rev., 2005, 18, 306-325.
147. Lim, H.M.; Pene, J.J., Shaw, R.W. Cloning, nucleotide sequence, and expression of the Bacillus cereus 5/B/6 β-lactamase II structural gene. J. Bacteriol., 1988, 170, 2873-78.
148. Massova, I.; Mobashery S. Kinship and diversification of bacterial penicillin-binding proteins and beta-lactamases. Antimicrob. Agents Chemother., 1998, 42, 1-17.
149. Lee, K.; Yum J.H.; Yong D.; Lee, H.M.; Kim H.D.; Docquier J.D.; Rossolini, G.M.; Chong Y. Novel acquired metallo-β-lactamase gene, blaSIM-1, in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea Antimicrob. Agents Chemother., 2005, 49, 4485-91.
150. Walther-Rasmussen, J.; Hoiby, N. OXA-type carbapenemases. J. Antimicrob. Chemother., 2006, 57, 373-83.
151. Turton, J.F.; Woodford, N.; Glover, J.; Yarde, S.; Kaufmann, M.E.; Pitt, T.L. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. J. Clin. Microbiol., 2006, 44, 2974-6.
152. Shibayama, T.; Matsushita, Y.; Hirota, T.; Ikeda, T.; Kuwaharam, S. Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers. Antimicrob. Agents Chemother., 2006, 50, 4186-8.